| Identification | Back Directory | [Name]
FWMUIOJZHOPPDX-UHFFFAOYSA-N | [CAS]
1638526-21-2 | [Synonyms]
EMT inhibitor-1
FWMUIOJZHOPPDX-UHFFFAOYSA-N
EMT inhibitor1,EMT inhibitor 1
1-Butanol, 4-[[4-(3,4-dichlorophenyl)-1,2,5-thiadiazol-3-yl]oxy]- | [Molecular Formula]
C12H12Cl2N2O2S | [MDL Number]
MFCD30747886 | [MOL File]
1638526-21-2.mol | [Molecular Weight]
319.21 |
| Chemical Properties | Back Directory | [Boiling point ]
443.3±45.0 °C(Predicted) | [density ]
1.415±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : ≥ 5.6 mg/mL (17.54 mM) | [form ]
Solid | [pka]
14.96±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
EMT inhibitor-1 is an inhibitor of of Hippo, TGF-β, and Wnt signaling pathways with antitumor activities. | [in vivo]
EMT inhibitor-1 (C19) (intraperitoneal injection; 5-20 mg/kg) exerts strong antitumor activity in a mouse tumor model. Mechanistically, EMT inhibitor-1 induces GSK3-β–mediated degradation of the Hippo transducer TAZ, through activation of the Hippo kinases Mst/Lats and the tumor suppressor kinase AMPK upstream of the degradation complex[1].C19 is dissolved in the vehicle solution (100 μL of DMEM containing 5% dimethyl sulfoxide). | [References]
[1] Basu D, et al. Identification, mechanism of action, and antitumor activity of a small molecule inhibitor of hippo, TGF-β, and Wnt signaling pathways. Mol Cancer Ther. 2014 Jun;13(6):1457-67. DOI:10.1158/1535-7163.MCT-13-0918 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|